Cyclooxygenase-2-selective Nonsteroidal Anti-Inflammatory Drugs Inhibit Hepatocyte Growth Factor/Scatter Factor-induced Angiogenesis

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8351-8359

  Sengupta, Shiladitya ^a,b   Sellers, Lynda A ^a,c   Cindrova, Tereza ^a   Skepper, Jeremy ^a   Gherardi, Ermanno ^a   Sasisekharan, Ram ^b   Fan, Tai Ping D ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CYCLOOXYGENASE 2; KETOPROFEN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYETHER; POLYURETHAN; PROSTAGLANDIN SYNTHASE; SCATTER FACTOR; XENON 133;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG MECHANISM; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DIVISION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENDOTHELIUM, VASCULAR; HEPATOCYTE GROWTH FACTOR; HUMANS; ISOENZYMES; LIPOXYGENASE; LIPOXYGENASE INHIBITORS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0345734269     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
2. Anderson, K. E., Johnson, T. W., Lazovich, D., and Folsom, A. R. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J. Natl. Cancer Inst., 94: 1168-1671, 2002.
3. Ristimaki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., Joensuu, H., and Isola, J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res., 62: 632-635, 2002.
4. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 231: 232-235, 1971.
5. Williams, C. S., Mann, M., and DuBois, R. N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18: 7908-7916, 1999.
6. van Rees, B. P., Saukkonen, K., Ristimaki, A., Polkowski, W., Tytgat, G. N., Drillenburg, P., and Offerhaus, G. J. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J. Pathol., 196: 171-179, 2002.
7. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
8. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.
9. Song, X., Lin, H. P., Johnson, A. J., Tseng, P. H., Yang, Y. T., Kulp, S. K., and Chen, C. S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst., 9: 585-591, 2002.
10. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.
11. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
12. Griffioen, A. W., and Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev., 52: 237-268, 2000.
13. Cristofanilli, M., Charnsangavej, C., and Hortobagyi, G. N. Angiogenesis modulation in cancer research: novel clinical approaches. Nat. Rev. Drug Discov., 1: 415-426, 2002.
14. Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., and Comoglio, P. M. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol., 119: 629-641, 1992.
15. Sengupta, S., Gherardi, E., Sellers, L. A., Wood, J. M., Sasisekharan, R., and Fan, T. P. Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol., 23: 69-75, 2003.
16. Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., Tashiro, K., and Shimizo, S. Molecular cloning and expression of human hepatocyte growth factor. Nature (Lond.), 342: 440-443, 1989.
17. Gherardi, E., Gray, J., Stoker, M., Perryman, M., and Furlong, R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc. Natl. Acad. Sci. USA, 86: 5844-5848, 1989.
18. Otte, J. M., Schmitz, F., Kiehne, K., Stechele, H. U., Banasiewicz, T., Krokowicz, P., Nakamura, T., Folsch, U. R., and Herzig, K. Functional expression of HGF and its receptor in human colorectal cancer. Digestion, 61: 237-246, 2000.
19. Lamzus, K., Jin, L., Fuchs, A., Shi, E., Chowdhury, S., Yao, Y., Polverini, P. J., Laterra, J., Goldberg, I. D., and Rosen, E. M. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab. Invest., 76: 339-353, 1997.
20. Cao, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., Wang, L. M., and Vande Woude, G. F. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA, 98: 7443-7448, 2001.
21. Abounader, R., Lal, B., Luddy, C., Koe, G., Davidson, B., Rosen, E. M., and Laterra, J. In vivo targeting of SF/HGF and c-met expression via UlsnRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J., 16: 108-110, 2002.
22. Jones, M. K., Sasaki, E., Halter, F., Pai, R., Nakamura, T., Arakawa, T., Kuroki, T., and Tarnawski, A. S. HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J., 13: 2186-2194, 1999.
23. Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., and Tamawski, A. S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 5: 1418-1423, 1999.
24. Born G. V. R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond.), 194: 927-929, 1962.
25. Hu, D. E., Hiley, C. R., Smither, R. L., Gresham, G. A., and Fan, T. P. Correlation of 133Xe clearance, blood flow and histology in the rat sponge model for angiogenesis. Further studies with angiogenic modifiers. Lab Invest., 72: 601-610, 1995.
26. Riendeau, D., Percival, M. D., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Falgueyret, J. P., Ford-Hutchinson, A. W., et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol., 121: 105-117, 1997.
27. Fan, T. P., Frost, E. E., and Wren, A. D. A multichannel wounding device for the study of vascular repair in vitro. EXS, 61: 315-320, 1992.
28. Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., and Isakson, P. C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA, 95: 13313-13318, 1998.
29. Tsopanoglou, N. E., Pipili-Synetos, E., and Maragoudakis, M. E. Leukotrienes C4 and D4 promote angiogenesis via a receptor-mediated interaction. Eur. Pharmacol. 258: 151-154, 1994.
30. McDonald, R. W., Bunjobpon, W., Liu, T., Fessler, S., Pardo, O. E., Freer, I. K., Glaser, M., Seckl, M. J., and Robins, D. J. Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues. Anticancer Drug Des., 16: 261-270, 2001.
31. Fan, Y. Y., Ramos, K. S., and Chapkin, R. S. Dietary gamma-linolenic acid modulates macrophage-vascular smooth muscle cell interactions. Evidence for a macrophage-derived soluble factor that downregulates DNA synthesis in smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 15: 1397-1403, 1995.
32. Haddad, R., Lipson, K. E., and Webb, C. P. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res., 21: 4243-4252, 2001.
33. Grierson, I., Heathcote, L., Hiscott, P., Hogg, P., Briggs, M., and Hagan, S. Hepatocyte growth factor/scatter factor in the eye. Prog. Retin. Eye Res., 19: 779-802, 2000.
34. Grant, D. S., Kleinman, H. K., Goldberg, I. D., Bhargava, M. M., Nickoloff, B. J., Kinsella, J. L., Polverini, P., and Rosen, E. M. Scatter factor induces blood vessel formation in vivo. Proc. Natl. Acad. Sci. USA, 90: 1937-1941, 1993.
35. Nagashima, M., Hasegawa, J., Kato, K., Yamazaki, J., Nishigai, K., Ishiwata, T., Asano, G., and Yoshino, S. Hepatocyte growth factor (HGF), HGF activator, and c-Met in synovial tissues in rheumatoid arthritis and osteoarthritis. J. Rheumatol., 28: 1772-1778, 2001.
36. Matsumoto, K., Okazaki, H., and Nakamura, T. Novel function of prostaglandins as inducers of gene expression of HGF and putative mediators of tissue regeneration. J. Biochem (Tokyo), 117: 458-464, 1995.
37. Hori, T., Shibamoto, S., Hayakawa, M., Takeuchi, K., Oku, N., Miyazawa, K., Kitamura, N., and Ito, F. Stimulation of prostaglandin production by hepatocyte growth factor in human gastric carcinoma cells. FEBS Lett., 334: 331-334, 1993.
38. Brzozowski, T., Konturek, P. C., Konturek, S. J., Schuppan, D., Drozdowicz, D., Kwiecien, S., Majka, J., Nakamura, T., and Hahn, E. Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2. Digestion, 64: 15-29, 2001.
39. Ziche, M., Jones, J., and Gullino, P. M. Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst., 69: 475-482, 1982.
40. Reed, M. J., Corsa, A., Pendergrass, W., Penn, P., Sage, E. H., and Abrass, I. B. Neovascularization in aged mice: delayed angiogenesis is coincident with decreased levels of transforming growth factor beta1 and type I collagen. Am. J. Pathol., 152: 113-123, 1998.
41. Vane, J. R., Bakhle, Y. S., and Botting, R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 38: 97-120, 1998.
42. Fleischmann, R., Iqbal, I., and Slobodin, G. Meloxicam. Expert Opin. Pharmacother., 3: 1501-1512, 2002.
43. Reiter, R., Resch, U., and Sinzinger, H. Do human platelets express COX-2? Prostaglandins Leukot. Essent. Fatty Acids, 64: 299-305, 2001.
44. Koike, H., Morishita, R., Iguchi, S., Aoki, M., Matsumoto, K., Nakamura, T., Yokoyama, C., Tanabe, T., Ogihara, T., and Kaneda, Y. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J., 17: 779-781, 2003.
45. Daniel, T. O., Liu, H., Morrow, J. D., Crews, B. C., and Marnett, L. J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res., 59: 4574-4577, 1999.
46. Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., Kobayashi, M., Satoh, K., Narita, M., Sugimoto, Y., Murata, T., Yoshimura, H., Narumiya, S., and Majima, M. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med., 197: 221-232, 2003.
47. Zeng, Z. Z., Yellaturu, C. R., Neeli, I., and Rao, G. N. 5(S)-hydroxyeicosatetraenoic acid stimulates DNA synthesis in human microvascular endothelial cells via activation of Jak/STAT and PI3-kinase/Akt signaling leading to induction of expression of basic fibroblast growth factor-2. J. Biol. Chem., 277: 41213-41219, 2002.
48. Lauder, H., Frost, E. E., Hiley, C. R., and Fan, T-P. D. Quantification of the repair process involved in the repair of a cell monolayer using an in vitro model of mechanical injury. Angiogenesis, 2:67-80, 1998.
49. Murphy, J. F., and Fitzgerald, D. J. Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor. FASEB J., 15: 1667-1669, 2001.
50. Hernandez, G. L., Volpert, O. V., Iniguez, M. A., Lorenzo, E., Martinez-Martinez, S., Grau, R., Fresno, M., and Redondo, J. M. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med., 193: 607-620, 2001.
51. Dormond, O., Foletti, A., Paroz, C., and Ruegg, C. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med., 7: 1041-1047, 2001.
52. Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., and DuBois, R. N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res., 58: 362-366, 1998.
53. Yamamoto, K., Morishita, R., Hayashi, S., Matsushita, H., Nakagami, H., Moriguchi, A., Matsumoto, K., Nakamura, T., Kaneda, Y., and Ogihara, T. Contribution of Bcl-2, but not Bcl-xL and Bax, to antiapoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension, 37: 1341-1348, 2001.
54. Sengupta, S., Sellers, L. A., Li, R. C., Gherardi, E., Zhao, G., Watson, N., Sasisekharan, R., and Fan, T. P. Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation, 107: 2955-2961, 2003.
55. Tang, Q., Gonzales, M., Inoue, H., and Bowden, G. T. Roles of Akt and glycogen synthase kinase 3β in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res., 61: 4329-4332, 2001.
56. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., Schnitzer, T. J., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 343: 1520-1528, 2000.
57. Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M., and Geis, G. S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J. Am. Med. Assoc., 284: 1247-1255, 2000.
58. Leahy, K. M., Ornberg, R. L., Wang, Y., Zweifel, B. S., Koki, A. T., and Masferrer, J. L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res., 62: 625-631, 2002.